Journal
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
Volume 25, Issue 6, Pages 1215-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2011.10.002
Keywords
Acute promyelocytic leukemia; All-trans retinoic acid; Arsenic trioxide; Targeted therapies; Cure
Categories
Funding
- NCI NIH HHS [R25 CA020449, T32 CA009207] Funding Source: Medline
Ask authors/readers for more resources
The introduction of all-trans retinoic acid to anthracycline-based chemotherapy has revolutionized the prognosis of patients with acute promyelocytic leukemia (APL). The introduction of arsenic trioxide enabled the therapeutic approach of rationally targeted frontline protocols with minimal or no traditional cytotoxic chemotherapy and without compromise of previously established outstanding outcomes with anthracycline-based regimens. Although most of the current investigative efforts in APL are focused on developing potentially curative therapy without the exposure to toxicities and risks of DNA-disrupting agents, the cure rate can further be increased by implementing meticulous supportive care strategies that counter early coagulopathy-related deaths.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available